Saturday, February 17, 2024
NEW Indication For Xolair!!!On February 16, 2024, the US Food and Drug Administration (FDA) approved XOLAIR (omalizumab) for the reduction
of allergic reaction (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods in adults
and children aged 1 year and older with IgE-mediated food allergy. This is very exciting news for our severe food allergy
patients, who are constantly in fear of getting contaminiation and having a severe reaction. Both Dr Olivero and Dr
Stanaland have extensive experiance in prescribing Xolair. Dr. Stanaland has been using Xolair since 1991 when he was
a clinical investigator in a trial with severe steroid dependant asthma patients. The current clinical indications for
Xolair include Severe Asthma, Chronic Spontaneous Urticaria, Chronic Rhinosinusitis with Nasal Polyps and now preventions
of Food induced anaphylaxis.
8:35 am est
|